Annexon, Inc. reported second quarter 2026 financial results and announced key clinical milestones for its neuroinflammatory drug pipeline. The company posted a net loss of $55.3 million, or $0.28 per share, compared to $49.2 million in the prior year period. R&D expenses rose to $46.6 million from $44.2 million, while G&A expenses increased to $10.6 million from $7.6 million. Cash and short-term investments stood at $209.2 million as of June 30, 2026, with an anticipated runway extending into 2028 supported by a new $200 million credit facility. Clinically, the Phase 3 ARCHER II trial for vonaprument in geographic atrophy added a Month 24 dual primary endpoint and launched an open-label extension study; the Month 15 data readout is expected in Q4 2026. Additionally, a BLA submission for tanruprubart in Guillain-Barré syndrome is targeted for Q4 2026. Annexon operates as a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases.

Annexon, Inc. announced the immediate resignation of Muneer Satter from its Board of Directors and all committees after more than eleven years of service. Simultaneously, the company appointed Mark S. Blumenkranz, M.D., M.M.S., a renowned retinal surgeon and biotechnology entrepreneur, as a Class II director effective August 10, 2026. Dr. Blumenkranz will serve on the Audit Committee and Science and Technology committee. He received an initial stock option grant for 175,000 shares in lieu of the standard annual automatic grant. Mr. Satter's departure was not due to any disagreements regarding operations or strategy. Annexon is a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases.

Annexon, Inc. issued a press release on August 6, 2026, reporting early clinical data from the open-label FORWARD study of tanruprubart for Guillain-Barré syndrome (GBS). The initial cohort included ten U.S. and European patients who demonstrated rapid improvement in muscle strength within four days and reduced disability following a single infusion of 30 mg/kg tanruprubart. Four bedbound patients regained the ability to walk between day two and eight, and one ventilated patient was extubated within four days. These results reinforce consistency with Phase 3 findings where approximately 90% of patients showed improvement by day 8. The data is expected to support a Biologics License Application (BLA) submission targeted for Q4 2026, while the Marketing Authorisation Application remains under review by the European Medicines Agency. Annexon operates in the biopharmaceutical industry, developing targeted immunotherapies for neuroinflammatory diseases.

Annexon, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC on July 30, 2026, securing a strategic credit facility for up to $200 million in term loans. The company drew an initial tranche of $50 million at closing, with additional tranches available upon achieving specified milestones related to its vonaprument and tanruprubart programs or through mutual agreement. Interest accrues at the greater of 1-Month CME Term SOFR plus 4.6% or 7.60%, with maturity dates ranging from July 2031 to June 2032 depending on milestone achievement. Monthly interest-only payments are required until September 2029, extendable based on performance, after which principal and interest repayments commence. This non-dilutive financing strengthens the balance sheet as the company advances its product candidates toward potential global commercialization. Annexon is a biopharmaceutical company developing targeted immunotherapies for neuroinflammatory diseases.